INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $878,000 | -18.2% | 8,083 | +23.9% | 0.00% | 0.0% |
| Q3 2016 | $1,074,000 | +17.4% | 6,526 | +1.8% | 0.00% | 0.0% |
| Q2 2016 | $915,000 | +19.1% | 6,410 | +7.3% | 0.00% | 0.0% |
| Q1 2016 | $768,000 | -66.1% | 5,975 | -60.6% | 0.00% | -66.7% |
| Q4 2015 | $2,264,000 | -9.4% | 15,158 | +0.6% | 0.00% | 0.0% |
| Q3 2015 | $2,500,000 | -35.5% | 15,070 | -6.1% | 0.00% | -40.0% |
| Q2 2015 | $3,876,000 | +24.8% | 16,056 | +45.8% | 0.01% | +25.0% |
| Q1 2015 | $3,105,000 | +374.0% | 11,011 | +162.2% | 0.00% | +300.0% |
| Q4 2014 | $655,000 | -35.8% | 4,199 | -2.6% | 0.00% | 0.0% |
| Q3 2014 | $1,020,000 | -2.8% | 4,309 | -2.8% | 0.00% | 0.0% |
| Q2 2014 | $1,049,000 | -83.9% | 4,433 | -77.6% | 0.00% | -88.9% |
| Q1 2014 | $6,527,000 | +385.6% | 19,791 | +0.6% | 0.01% | +350.0% |
| Q4 2013 | $1,344,000 | -1.5% | 19,678 | -0.4% | 0.00% | 0.0% |
| Q3 2013 | $1,364,000 | +85.3% | 19,764 | +20.5% | 0.00% | +100.0% |
| Q2 2013 | $736,000 | – | 16,408 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |